HSG Holding’s Barinthus Biotherapeutics BRNS Stock Holding History

HSG Holding’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$938K	Hold	1,420,473	–	–	0.08%	18
2026 Q1	$1.16M	Hold	1,420,473	–	–	0.07%	16
2025 Q4	$42.2M	Hold	1,420,473	–	–	2.23%	7
2025 Q3	$1.96M	Hold	1,420,473	–	–	0.1%	16
2025 Q2	$1.32M	Hold	1,420,473	–	–	0.07%	17
2025 Q1	$1.16M	Hold	1,420,473	–	–	0.07%	15
2024 Q4	$1.39M	Hold	1,420,473	–	–	0.06%	16
2024 Q3	$1.89M	Hold	1,420,473	–	–	0.07%	16
2024 Q2	$1.95M	Hold	1,420,473	–	–	0.07%	15
2024 Q1	$3.62M	Hold	1,420,473	–	–	0.34%	13
2023 Q4	$4.3M	Hold	1,420,473	–	–	0.5%	14
2023 Q3	$4.39M	Hold	1,420,473	–	–	0.47%	16
2023 Q2	$2.93M	Hold	1,420,473	–	–	0.33%	15
2023 Q1	$3.18M	Hold	1,420,473	–	–	0.33%	14
2022 Q4	$3.34M	Hold	1,420,473	–	–	0.34%	14
2022 Q3	$4.55M	Hold	1,420,473	–	–	0.49%	15
2022 Q2	$6.32M	Buy	+1,420,473	New	+$6.84M	0.58%	13

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

GLR Partners Columbia, Maryland $215M AUM

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HSG Holding's BRNS Position: Q2 2026 in Review

HSG Holding held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 1,420,473 shares worth $938K. The position accounts for 0.08% of the portfolio, ranked #18.

HSG Holding first reported a position in BRNS in Q2 2022 and has held it in 17 quarters since. The position peaked at $42.2M in Q4 2025. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

HSG Holding held 1,420,473 shares of Barinthus Biotherapeutics worth $938K as of Q2 2026.
HSG Holding left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
Barinthus Biotherapeutics made up 0.08% of HSG Holding's portfolio in Q2 2026, its #18 holding.
HSG Holding first reported a position in Barinthus Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
HSG Holding's Barinthus Biotherapeutics position peaked at $42.2M in Q4 2025.
15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on HSG Holding's 13F filing for Q2 2026, filed 13 Aug 2026.